First CRISPR Baby to Survive and Thrive!
Recently, a six-month-old boy named KJ Muldoon has become the face of a new era in medicine: personalized CRISPR gene therapy. Born with a deadly liver disorder called CPS1 deficiency, KJ was given just months to live. But thanks to a customized CRISPR base-editing treatment, he’s not only surviving—he’s thriving.
Developed in record time and delivered directly to his liver via lipid nanoparticles, the therapy precisely corrected the single mutation causing his condition. After just a few months of treatment, KJ is now tolerating protein, off most of his medications, and meeting all his developmental milestones.
This is not the kind of gene editing that sparked global backlash in 2018 with embryo modifications in China. KJ’s treatment was ethically approved, highly targeted, and conducted under strict clinical oversight.
While it’s still early, this one-patient success hints at a future where rare genetic diseases could be treated not in decades—but in months—through precision editing tailored to each individual’s DNA.
The CRISPR revolution isn’t coming. It’s already here.
Comments